公开(公告)号：US20240101662A1

公开(公告)日：2024-03-28

申请号：US18513931

申请日：2023-11-20

Applicant: Janssen Biotech, Inc.

Inventor： Ming-Chun Hsu ,  Shu Li ,  Bruce Randazzo ,  Kun Song ,  Yaowei Zhu

IPC: C07K16/24 ,  A61P17/06

CPC classification number: C07K16/244 ,  A61P17/06 ,  A61K2039/505

Abstract: Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.

公开(公告)号：US20200331996A1

公开(公告)日：2020-10-22

申请号：US16819629

申请日：2020-03-16

Applicant: Janssen Biotech, Inc.

Inventor： Ming-Chun Hsu ,  Shu Li ,  Bruce Randazzo ,  Kun Song ,  Yaowei Zhu

IPC: C07K16/24 ,  A61P17/06

Abstract: Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.

公开(公告)号：US20230014839A1

公开(公告)日：2023-01-19

申请号：US17931633

申请日：2022-09-13

Applicant: Janssen Biotech, Inc.

Inventor： Ming-Chun Hsu ,  Shu Li ,  Bruce Randazzo ,  Kun Song ,  Yaowei Zhu

IPC: C07K16/24 ,  A61P17/06

Abstract: Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.

公开(公告)号：US20220144946A1

公开(公告)日：2022-05-12

申请号：US17519811

申请日：2021-11-05

Applicant: Janssen Biotech, Inc.

Inventor： Sindhu Ramchandran ,  Hong Sun ,  William Denney ,  Santiago Arroyo ,  Leona Ling ,  Jocelyn Leu ,  Jianhua Jin ,  Marie-Helene Jouvin ,  Keith Karcher ,  Shawn Black ,  Yaowei Zhu

IPC: C07K16/28 ,  A61P21/04 ,  A61K47/26 ,  A61K47/10

Abstract: Methods for dosing of antibodies to human neonatal Fc receptor (FcRn) are described. The anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, or to treat immunological diseases (e.g., autoimmune diseases) in a subject.

公开(公告)号：US20220073603A1

公开(公告)日：2022-03-10

申请号：US17389533

申请日：2021-07-30

Applicant: Janssen Biotech, Inc.

Inventor： Ming-Chun Hsu ,  Shu Li ,  Bruce Randazzo ,  Kun Song ,  Yaowei Zhu

IPC: C07K16/24 ,  A61P17/06

Abstract: Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.